Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

Study ID
NCT02826486

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

COMBAT

Trial Summary

This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.

More informations

Trial Starting Date

Sep 30,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit